Rodman David Malcom 4

What Happened Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), exercised 417 stock options and immediately sold the resulting 417 shares in an open-market transaction on February 17, 2026. The options were exercised at $15.44 per share (total exercise cost $6,438) and the shares were sold at $27.59 per share (gross proceeds $11,505), yielding a gross difference of $5,067 before taxes and fees. The filing shows the derivative (the option) was converted and the shares disposed the same day.

Key Details

• Transaction date: 2026-02-17.
• Exercise: 417 shares at $15.44 each — total cost $6,438.
• Sale: 417 shares at $27.59 each — gross proceeds $11,505.
• Derivative reporting: 417 option shares were converted/disposed (reported as M/derivative).
• Plan/footnote: Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted Oct 6, 2025 (Footnote F1).
• Vesting note: The option vests 25% after one year, then monthly over 36 months (Footnote F2).
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• Filing timeliness: Reported on the same date as the transactions (no late filing indicated).

Context This was an option exercise with an immediate open-market sale of the resulting shares—commonly a liquidity or tax-management event. The presence of a 10b5-1 plan indicates these trades were prearranged. Sales by insiders can be routine and do not necessarily signal a change in company outlook; purchases generally carry more informational weight for investors.